Table 1 cDC1 cells in cancer immunity

Bladder cancer

Preclinical

cDC1 and CD8⁺ T cells confer immune surveillance and responses to intravesical CD40 agonism

[75]

Breast cancer

Preclinical

Anti-TIM-3 antibody improved response to paclitaxel chemotherapy was cDC1 dependent

[45]

Breast cancer

Correlative

Gene signatures of cDC1 were associated with increased overall survival

[40]

Breast and pancreatic cancer

Preclinical

Tumor-produced granulocyte-stimulating factor downregulated IRF8 in cDC progenitors and interrupted cDC1 development

[50]

Breast cancer (LBC, TNBC)

Correlative

Gene signatures of cDC1 are associated with increased overall patient survival

[39]

Breast cancer

Preclinical

cDC1 interferon signaling was required for T-cell mediated protective responses to breast cancer

[76]

Fibrosarcoma

Preclinical

Rejection of tumors was impaired in cDC1 deficient mice

[77]

Fibrosarcoma

Preclinical

Lack of CD103⁺ DC within the tumor microenvironment dominantly resists the effector phase of an anti-tumor T cell response, contributing to immune escape

[44]

Hepatocellular carcinoma

Preclinical

CD47 blockade enhanced tumor DNA uptake by cDC1 and stimulated the cGAS-STING-dependent infiltration of NK cells in liver cancer

[78]

Liver-engrafted tumors

Preclinical

Depletion of cDC1 in established tumors suppressed immunotherapy efficacy of anti-PD-1 and/or anti-CD137 as well as adoptive T-cell therapy

[79]

Lung cancer

Prognostic and in vitro

cDC1s cross-present human tumor antigen after uptake of necrotic lung cancer cells

[80]

Lung carcinoma and melanoma-induced lung metastasis

Preclinical

Lung tumor development led to the accumulation of regulatory CD103^loCD11b⁺ DC and a reduced proportion of cDC1

[81]

Non-small cell lung cancer (NSCLC)

Preclinical

Paucity of cDC1s contributes to reduced antitumor immunity

[82]

Melanoma

Preclinical

Recruitment of cDC1s into tumors was necessary for a CD8⁺ T cell responses

[83]

Melanoma

Preclinical

Efficacy of immunomodulatory anti-CD137 and anti-PD-1 immunotherapy required cDC1

[84]

Melanoma

Preclinical

cDC1 transported antigens to lymph nodes and primed CD8⁺ T cells and promoted anti-tumor effects upon PD-L1 ICI. Combined FLT3L and poly I:C therapy enhanced tumor responses to checkpoint and BRAF blockade

[46]

Melanoma

Preclinical

cDC1 enhanced activation of TCR-engineered T cells

[85]

Melanoma

Predictive

cDC1 among total antigen-presenting cells predicted patient responsiveness to anti-PD-1 therapy

[86]

Melanoma and osteosarcoma

Preclinical

Vaccination with poly I:C-activated and tumor antigen-loaded cDC1s enhanced tumor infiltration of tumor antigen-specific and interferon-γ⁺ CD8⁺ T cells, and suppressed tumor growth

[87]

Melanoma

Preclinical

Administration of Fms-related tyrosine 3 ligand (Flt3L) plus polyI:C and anti-CD40 resulted in an increase of activated cDC1 treated tumors and delayed tumor growth

[88]

Melanoma

Correlative

Human CD141⁺ cDC1 from blood are impaired in patients with advanced melanoma

[89]

Melanoma

Preclinical

Inhibition of the mevalonate pathway in cancer cells triggers cDC1-mediated anticancer immunity

[90]

Melanoma, colorectal cancer

Preclinical

Therapeutic efficacy dead cell antigen-loaded cDC1s was synergistic with anti-PD-1 therapy

[91]

Melanoma, colorectal carcinoma; several human cancer types

Preclinical; prognostic

FLT3LG and CCL5 or CCR5 gene expression signatures correlate with an enhanced cDC1 signature and a favorable overall survival in patients with cancer

[54]

Multiple human tumor biopsies

Correlative

Abundance of cDC1 transcripts correlated with clinical outcome

[92]

Ovarian cancer

Preclinical

PD-1 blockade enabled tumor-associated cDC1s to promote disease clearance

[93]

Ovarian cancer (OvC) and prostate cancer (PrC)

Correlative

cDC1s are reduced in patients with OvC, and are quantitatively and qualitatively impaired in patients with OvC or PrC

[56]

Pancreatic ductal adenocarcinoma (PDAC)

Preclinical

PDAC antigen-loaded cDC1s used as a vaccine, rendering PDAC sensitive to ICI with curative outcome

[94]